Answers are grounded in this paper and cite their sources.
Case report reveals effectiveness of CAR T-cell therapy in renal complications from monoclonal gammopathy, suggesting new treatment avenues.
Abstract: A 63-year-old woman with IgG Kappa monoclonal gammopathy of undetermined significance (MGUS) presented with progressive proteinuria and kidney dysfunction. Sequential biopsies eventually revealed collapsing focal segmental glomerulosclerosis ( FSGS) with light chain crystalline podocytopathy (LCCP), diagnostic of monoclonal gammopathy of renal significance (MGRS). Despite multiple clone-directed regimens, she progressed to kidney failure. Treatment with ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T-cell therapy, achieved complete hematologic remission sustained at 6 months. This case highlights the therapeutic potential of CAR T-cell therapy for refractory MGRS and evolving considerations for kidney transplantation following deep clonal remission.
No takes yet. Share an insight, caveat, or question.
Haddad et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: